Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2011

View Archived Issues

Studies assess 2-year and sustained-release ONO-5334 therapy

Merck & Co. assesses new agents potentiating beta-lactam antibiotics against MRSA

New serotonin 5-HT3 receptor partial agonists developed for irritable bowel syndrome

Kancera products show activity against pancreatic cancer cells

Vernalis and Servier reach milestone in oncology collaboration

Nanotherapeutics receives U.S. government contract to develop oral radiation drug

Threshold Pharmaceuticals begins pivotal study of TH-302

Pfizer reports topline phase III data on combination therapy for invasive aspergillosis

BIO-11006 is efficacious in phase IIa trial

AstraZeneca presents novel DNA gyrase inhibitors

New TTK inhibitors synthesized by Bayer Schering Pharma

Chinese institute discloses novel angiotensin AT1 receptor antagonists

Orexo presents novel phosphodiesterase 4 inhibitors

Roche patents new TYK2 inhibitors

Novel chemokine CCR2 receptor antagonists prepared by AstraZeneca

Second phase IIb trial of ALKS-37 begins for opioid-induced constipation

Phase IIb trial of SB-509 does not meet primary or secondary endpoints

Xoma's botulism program receives support from NIAID

Pfizer launches BeneFIX RTS in Europe

Phase III study of Cx-601 receives financial support

EMA accepts MAA for IB-1001

MedImmune in-licenses tremelimumab from Pfizer

Enrollment completed in GeoVax's HIV/AIDS vaccine study

Array BioPharma reports results from selumetinib NSCLC study

Update on Adventrx's NDA for Exelbine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...